MorphoSys and GlaxoSmithKline Partner in Antibody Pact

Article

-

MorphoSys has formeda global agreement with GlaxoSmithKline (GSK) to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody for treating mild to moderate rheumatoid arthritis. Under the agreement, GSK assumes responsibility for all subsequent development and commercialization of MOR103. MorphoSys receives an immediate upfront payment of EUR 22.5 million ($29.4 million) and up to EUR 423 million ($552 million), in addition to tiered, double-digit royalties on net sales, based on achieving certain developmental, regulatory, commercial and sales-based milestones.

Recent Videos
David Fairen-Jimenez
William K. Oh, MD
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Behind the Headlines episode 5
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content
An illustration of the glycan code showcasing the diversity of potential glycosylation patterns and their impact on protein function | Image Credit: © Justlight.

Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics

Christopher Cole
May 28th 2025
Article

Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.

Sanofi logo at one of skyscraper. Sanofi is a French biopharma company | Image Credit: © Robert - stock.adobe.com

Sanofi to Acquire Vigil Neuroscience to Expand Neurodegenerative Disease Pipeline

Christopher Cole
May 23rd 2025
Article

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its early-stage neurology pipeline.

Genetic engineering concept. Collage with glowing DNA molecule over female hand on blue background | Image Credit: © Prostock-studio

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.

3d rendered illustration of platelets | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

PL BioScience, DewCell Biotherapeutics to Develop Scalable Animal-Free Cell Culture Media

Patrick Lavery
May 21st 2025
Article

A letter of intent has been signed by the two companies for supply of artificial platelet raw material.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Vesicor Therapeutics Enters into Business Agreement with Black Hawk to Advance Oncology Treatments

Susan Haigney
April 29th 2025
Article

Black Hawk’s subsidiary, BH Merger Sub, will merge with Vesicor as part of the agreement.

Image Credit: © Tiero - stock.adobe.com

Biotherapeutics Partnerships and Innovation Expanding

Patrick Lavery
April 28th 2025
Article

Groundbreaking clinical studies and new research collaborations are pushing ahead even as uncertainty lingers about the geopolitical climate’s impact on development.

© 2025 MJH Life Sciences

All rights reserved.